Literature DB >> 18613782

Adjustable continence therapy for treatment of recurrent female urinary incontinence.

Ervin Kocjancic1, Simone Crivellaro, John Joseph Smith, Stefania Ranzoni, Daniele Bonvini, Bruno Frea.   

Abstract

PURPOSE: The Adjustable Continence Therapy (ACT) device has been developed for the treatment of recurrent stress urinary incontinence resulting from intrinsic sphincter deficiency (ISD) by increasing urethral coaptation. We critically evaluated the technique and its results.
METHODS: The ACT device consists of two balloons each attached to an injectable port placed in the labia majora. The port enables postoperative adjustment in balloon coaptation pressure. All 49 patients had previously failed anti-incontinence surgery. Each patient was implanted with the ACT device and assessed by preoperative and postoperative overall impression, incontinence quality of life questionnaire, and visual analog scale; 38 of the 49 subjects had a minimum of 1 year of data collected, including pad use, number of adjustments needed, and complications.
RESULTS: Mean operative time was 20.3 minutes (range 10-30 minutes), with 88% of implantations performed using local or regional anesthesia. Balloon adjustments were needed in 62%; 68% of patients reported being dry and 16% improved. Complications included migration (12%), balloon failure (3.6%), and erosion (4%).
CONCLUSION: The ACT device provided significant improvement in at last 70% of patients with recurrent stress urinary incontinence.

Entities:  

Mesh:

Year:  2008        PMID: 18613782     DOI: 10.1089/end.2008.0027

Source DB:  PubMed          Journal:  J Endourol        ISSN: 0892-7790            Impact factor:   2.942


  7 in total

1.  Functional outcomes of adjustable continence therapy (ACT™) balloons in women aged >80 years and suffering from stress urinary incontinence caused by intrinsic sphincter deficiency.

Authors:  Claire Billault; Emmanuel Chartier-Kastler; Morgan Rouprêt; Gilberte Robain; Véronique Phé
Journal:  World J Urol       Date:  2015-02-21       Impact factor: 4.226

Review 2.  Outcome measures for stress urinary incontinence treatment: can we minimally agree?

Authors:  Véronique Phé; Philippe Zimmern; Emmanuel Chartier-Kastler
Journal:  World J Urol       Date:  2015-03-20       Impact factor: 4.226

3.  Treatment of moderate to severe female stress urinary incontinence with the adjustable continence therapy (ACT) device after failed surgical repair.

Authors:  Sherif R Aboseif; Pejvak Sassani; Ethan I Franke; Steven D Nash; Joel N Slutsky; Neil H Baum; Mai Le Tu; Niall T Galloway; Peter J Pommerville; Suzette E Sutherland
Journal:  World J Urol       Date:  2010-10-20       Impact factor: 4.226

4.  Adjustable Continence Therapy (ACT®) balloons to treat female stress urinary incontinence: effectiveness, safety and risk factors of failure and complication.

Authors:  Marie-Liesse de Guerry; Amélie Demeestere; Christophe Bergot; Astrid de Hauteclocque; Juliette Hascoet; Anne-Sophie Bajeot; Camille Ternynck; Xavier Gamé; Benoît Peyronnet; Grégoire Capon; Marie-Aimée Perrouin-Verbe; Xavier Biardeau
Journal:  Int Urogynecol J       Date:  2022-06-25       Impact factor: 2.894

Review 5.  Management of recurrent stress incontinence following a sling.

Authors:  Geneviève Nadeau; Sender Herschorn
Journal:  Curr Urol Rep       Date:  2014-08       Impact factor: 3.092

Review 6.  Stress urinary incontinence in women.

Authors:  Pejvak Sassani; Sherif R Aboseif
Journal:  Curr Urol Rep       Date:  2009-09       Impact factor: 3.092

Review 7.  A systematic review of the treatment for female stress urinary incontinence by ACT® balloon placement (Uromedica, Irvine, CA, USA).

Authors:  Véronique Phé; Kien Nguyen; Morgan Rouprêt; Vincent Cardot; Jérôme Parra; Emmanuel Chartier-Kastler
Journal:  World J Urol       Date:  2013-06-20       Impact factor: 4.226

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.